

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnologie vzw

<120> A method for the identification of drug targets

<130> JVK-ChP-V127

<150> EP 02078801.4

<151> 2002-09-12

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide used in figure 3B and is acetylated.

<400> 1

Phe Ile Glu Gly Arg  
1 5

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> The peptide used in example 1.2: has an acetylated free alpha-NH2  
-terminus and a free COOH-terminus.

<400> 2

Phe	Ile	Glu	Gly	Arg	Ala	Asp	Ser	Lys	Ser	Ser
1				5					10	

<210> 3

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> The peptide in example 1.3; the Asp group carries an aldehyde,  
the first Ala is acetylated.

<400> 3

Ala	Ala	Ile	Glu	Gly	Arg	Tyr	Val	Ala	Asp
1				5					10

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> The peptide in example 1.3; the Asp group carries an aldehyde,  
the Tyr is acetylated.

<400> 4

Tyr Val Ala Asp

1

<210> 5

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> The peptide used in example 1.5 and Lys carries 19-actin-50.

<400> 5

Ala Asp Ser Lys Ser Ser  
1 5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide used in example 1.5; sequence from the compound peptide.

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> XAA can be any amino acid.

<400> 6

Ala Asp Ser Xaa Ser  
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide used in example 1.5; sequence derived from 19-27 actin  
sequence.

<400> 7

Ala Gly Phe Ala Gly Asp Asp Ala Pro  
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> The peptide is used in example 1.6: the NH2-terminal part of the  
compound peptide; the Phe is acetylated.

<400> 8

Phe Ile Glu Glu Arg  
1 5

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnologie vzw

<120> A method for the identification of drug targets

<130> 4465-6

<140> 10/527,662

<141> 2005-03-11

<150> EP 02078801.4

<151> 2002-09-12

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> purely synthetic peptide (used in figure 3B and is acetylated).

<400> 1

Phe Ile Glu Gly Arg  
1 5

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (The peptide used in example 1.2: has an acetylated free alpha-NH2-terminus and a free COOH-terminus).

<400> 2

Phe	Ile	Glu	Gly	Arg	Ala	Asp	Ser	Lys	Ser	Ser
1				5					10	

<210> 3

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> purely synthetic peptide (The peptide in example 1.3; the Asp gro up carries an aldehyde, the first Ala is acetylated).

<400> 3

Ala	Ala	Ile	Glu	Gly	Arg	Tyr	Val	Ala	Asp
1				5					10

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (The peptide in example 1.3; the Asp  
gro up carries an aldehyde, the Tyr is acetylated).

<400> 4

Tyr Val Ala Asp  
1

<210> 5

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (The peptide used in example 1.5 and  
Lys carries 19-actin-50).

<400> 5

Ala Asp Ser Lys Ser Ser  
1 5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (Peptide used in example 1.5; sequence  
f rom the compound peptide).

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> XAA can be any amino acid.

<400> 6

Ala Asp Ser Xaa Ser  
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (Peptide used in example 1.5; sequence  
d  
erived from 19-27 actin sequence).

<400> 7

Ala Gly Phe Ala Gly Asp Asp Ala Pro  
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Purely synthetic peptide (The peptide is used in example 1.6:  
the  
NH<sub>2</sub>-terminal part of the compound peptide; the Phe is  
acetylated  
).

<400> 8

Phe Ile Glu Glu Arg  
1 5